Key facts
- Ajax Therapeutics’s last known valuation is $192.5M.
- It has raised $143.0M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($95.0M) in May 2024.
- Notable investors include RA Capital Management, Point72 Ventures, Goldman Sachs Asset Management, Vivo Capital, EcoR1 Capital — 11 tracked in total.
- Ajax Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently May 2024 ($95.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Ajax Therapeutics
Funding rounds
3 roundsAbout Ajax Therapeutics
Developer of targeted therapy drugs designed for the treatment of hematologic cancers. The company leverages advances in molecular genetics and biology to develop new classes of therapies that are highly selective for specific drug targets, while aiming to minimize interactions with related proteins, enabling healthcare providers to access effective and precise treatment options for patients with blood cancers.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 9
- Website
- ajaxtherapeutics.com/
- Ownership
- Privately Held (backing)
Ajax Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ajax Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ajax Therapeutics in its N-PORT filings yet. We sweep new filings monthly.